Dr. Susana Navarro is a scientific researcher at the Division of Hematopoietic Innovative Therapies, CIEMAT, Madrid, Spain.
Her research has contributed to the development of gene therapy tools and preclinical studies for lentiviral-based gene therapy approaches targeting hematopoietic disorders such as Fanconi anemia (FA), pyruvate kinase deficiency (PKD), and Diamond-Blackfan anemia (DBA). She has played a key role in the design and follow-up of lentiviral gene therapy clinical trials and has participated in the development of five orphan drugs and five patents related to gene therapy treatments for these diseases.
In addition, she was instrumental in establishing the Good Manufacturing Practice (GMP) facility at the Biomedical Innovation Unit, where she served as a supervisor of the CliniStem production department for several years.
Currently, Dr. Susana Navarro leads a research project focused on the field of gene therapy for Diamond-Blackfan anemia and she´s developing a Phase I/II lentiviral gene therapy clinical trial for RPS19 deficient patients.